Article
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
The Lancet. Oncology - 1 Jan 2020
Mateo Joaquin, Porta Nuria, Bianchini Diletta, McGovern Ursula, Elliott Tony, Jones Robert, Syndikus Isabel, Ralph Christy, Jain Suneil, Varughese Mohini, Parikh Omi, Crabb Simon, Robinson Angus, McLaren Duncan, Birtle Alison, Tanguay Jacob, Miranda Susana, Figueiredo Ines, Seed George, Bertan Claudia, Flohr Penny, Ebbs Berni, Rescigno Pasquale, Fowler Gemma, Ferreira Ana, Riisnaes Ruth, Pereira Rita, Curcean Andra, Chandler Robert, Clarke Matthew, Gurel Bora, Crespo Mateus, Nava Rodrigues Daniel, Sandhu Shahneen, Espinasse Aude, Chatfield Peter, Tunariu Nina, Yuan Wei, Hall Emma, Carreira Suzanne, de Bono Johann S
Abstract excerpt
BACKGROUND: Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer. METHODS: In this open-label, investigator-initiated, randomised phase 2 trial following a selection (or pick-the-winner)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.